 |
|
| Parkinson's Disease Clinical Trials For posting and discussion of clinical trials related to Parkinson's Disease, and for the Parkinson Pipeline Project. All are welcome. |
| Reply |
|
|
Thread Tools | Display Modes |
04-04-2008, 06:56 PM
|
#1 | |||
|
||||
|
Magnate
|
ACADIA Pharmaceuticals Initiates Second Phase III Trial With Pimavanserin In Patients With Parkinson's Disease Psychosis
Main Category: Parkinson's Disease Article Date: 03 Apr 2008 - 1:00 PDT ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, announced that it has initiated its second Phase III trial designed to evaluate the safety and efficacy of pimavanserin as a treatment for Parkinson's disease psychosis (PDP). "The start of our second Phase III pivotal trial represents another important step forward toward our goal of providing a first-in-class treatment for patients with PDP," said Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA Pharmaceuticals. "We believe pimavanserin may provide a unique combination of antipsychotic efficacy, motoric tolerability and safety and, therefore, provides the potential for an important advance in therapy for patients suffering from this debilitating disorder." About Pimavanserin Pimavanserin tartrate is a novel, potent, and selective 5-HT2A inverse agonist that ACADIA discovered and is developing as a treatment for PDP. ACADIA is currently conducting two Phase III pivotal trials in its program with pimavanserin as a treatment for PDP. ACADIA has also reported positive results from a Phase II trial in its program with pimavanserin as a co-therapy for schizophrenia. READ more
__________________
You're alive. Do something. The directive in life, the moral imperative was so uncomplicated. It could be expressed in single words, not complete sentences. It sounded like this: Look. Listen. Choose. Act. ~~Barbara Hall I long to accomplish a great and noble tasks, but it is my chief duty to accomplish humble tasks as though they were great and noble. The world is moved along, not only by the mighty shoves of its heroes, but also by the aggregate of the tiny pushes of each honest worker. ~~Helen Keller |
|||
|
 Reply With Quote
|
|
04-14-2013, 03:36 PM
|
#2 | ||
|
|||
|
Senior Member
|
"Thu Apr 11, 2013 9:43am EDT
(Reuters) - Acadia Pharmaceuticals Inc said data from an initial late-stage trial would be sufficient to file for approval for its experimental antipsychotic drug for Parkinson's disease patients, ... Parkinson's disease psychosis is a debilitating disorder that develops in up to 60 percent of patients as their Parkinson's disease progresses. Most current antipsychotic drugs cannot be used in Parkinson's disease patients as they block dopamine in the brain, which is the primary target for Parkinson's therapy, and can lead to a worsening of motor functions in such patients. Pimavanserin works by selectively blocking certain serotonin receptors in the brain, but has no effect on dopamine..." http://www.reuters.com/article/2013/...93A0IA20130411 John
__________________
Born 1955. Diagnosed PD 2005. Meds 2010-Nov 2016: Stalevo(75 mg) x 4, ropinirole xl 16 mg, rasagiline 1 mg Current meds: Stalevo(75 mg) x 5, ropinirole xl 8 mg, rasagiline 1 mg |
||
|
|
Reply With Quote
|
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| REBATE CARD: zelaCARD for Parkinson's Disease Patients Taking Zelapar(R) [Selegiline] | Parkinson's Disease | |||
| CLINICAL TRIAL...Phase III Trial with Pimavanserin in Patients with PD Psychosis | Parkinson's Disease Clinical Trials | |||
Phase III: Pimavanserin In Patients With Parkinson's Disease Psychosis
Linear Mode
